A Phase II Study of SarNU (NSC 364432) in Patients with Malignant Glioma.

Trial Profile

A Phase II Study of SarNU (NSC 364432) in Patients with Malignant Glioma.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Mar 2016

At a glance

  • Drugs NSC 364432 (Primary)
  • Indications Anaplastic astrocytoma; Glioblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Sep 2013 Additional lead trial centre added as reported by ClinicalTrials.gov.
    • 16 Mar 2010 Actual end date (Sep 2008) added as reported by ClinicalTrials.gov.
    • 16 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top